Can a common parasite medication calm the brain’s stress circuitry during alcohol withdrawal?

Alcohol use disorder affects tens of millions of people globally, resulting in massive economic costs and severe public health consequences. The chronic condition is defined by an inability to control drinking habits and the emergence of severe negative emotional states when the substance is removed.

While several medications are approved to treat the disorder, they only work for a fraction of patients. In a recent study, researchers found that genetic markers related to a specific brain receptor predict the severity of alcohol dependence in rodents, and that administrating the anti-parasitic drug ivermectin reduces withdrawal-driven drinking. The study was published in the journal Neuropharmacology.

Current pharmaceutical treatments for alcohol use disorder often fail to provide lasting relief because patients possess wide biological and genetic diversity. A chemical intervention that successfully curbs drinking in one person might produce side effects or show no measurable effect in another. For psychiatric treatments to improve, the medical field must adopt a precision medicine model that accounts for these deeply ingrained individual differences.

A collaborative team of scientists, led by Paola Campo, Marsida Kallupi, and Giordano de Guglielmo at the University of California San Diego, sought to understand how specific genetic variations influence addiction behaviors. They focused on a gene called *P2rx4*. This gene contains the instructions for building the P2X4 receptor, a specialized protein channel located on the surface of brain cells.

These receptors are highly concentrated in areas of the brain associated with stress and reward processing. Under normal conditions, they help regulate the flow of electrical signals between neurons. When an individual consumes alcohol, the substance acts as an inhibitor, temporarily dampening the activity of these receptor channels.

Free daily newsletter

In response to chronic alcohol exposure, the brain attempts to compensate by producing more of these receptors. Previous research linked this receptor cluster to drinking behaviors in various animal models, but the exact relationship remained largely unexplored in a naturally diverse genetic population. The research team hypothesized that baseline variations in this gene might dictate which individuals are most vulnerable to escalating their drinking over time.

To test this idea, the researchers utilized heterogeneous stock rats. Unlike traditional laboratory strains that are bred to be genetically identical, heterogeneous stock rats are bred from eight different source populations. This breeding strategy creates a large gene pool, producing rodents with distinct physical traits and behavioral tendencies that more closely mirror human diversity.

Rather than directly tracking the physical proteins in the brains of live animals, the researchers applied an advanced computational model to an existing genetic database. They examined specific variations in the DNA sequence located near the target gene. By analyzing these tiny genetic spelling differences across 131 distinct rats, the tools predicted how robustly the gene would be expressed in each animal’s brain tissue.

Based on these statistical calculations, the team separated the rodents into a high predicted expression group and a low predicted expression group. The animals were initially trained in specialized conditioning chambers, where they learned to press a mechanical lever to receive small liquid drops of alcohol.

After establishing a stable baseline of voluntary consumption, the researchers exposed the rodents to a daily cycle of alcohol vapor within their housing units. This chronic intermittent vapor model replicates human physical dependence by maintaining highly elevated blood alcohol levels for extended stretches, followed by periods of forced abstinence.

The researchers found that rodents assigned to the high predicted expression group escalated their alcohol intake much more severely during withdrawal compared to the other animals. Both groups drank more alcohol after becoming dependent, but the genetically susceptible rats exhibited a much heavier burden of compulsive drinking.

Following this genetic analysis, the researchers explored a potential pharmaceutical intervention. They tested ivermectin, a common medication typically prescribed in veterinary and human medicine to treat parasitic worm infections. Earlier cellular studies demonstrated that ivermectin acts on the P2X4 receptor and boosts its activity, essentially counteracting the biological dampening effects caused by alcohol.

A separate cohort of 32 dependent, genetically diverse rodents received varying doses of ivermectin via injection four hours before behavioral testing. The drug produced a dose-dependent reduction in alcohol consumption. Animals given the highest doses markedly reduced their lever-pressing for alcohol during acute withdrawal periods.

The researchers also needed to ensure that the medication was directly altering the brain’s motivation system rather than merely making the animals physically sluggish. They monitored the rodents’ water intake throughout the pharmacological testing. The medication did not alter the animals’ desire to drink water, confirming that it specifically reduced alcohol-seeking behavior without causing generalized motor deficits.

However, the researchers observed a discrepancy between the sexes. Female rodents consumed more alcohol on average and required a higher dose of ivermectin to display a drop in drinking compared to the male subjects. Because of the widespread genetic diversity among the subjects, the medication did not work universally across the entire population.

The researchers stratified the animals based on their specific behavioral responses to the drug, categorizing them as non-responders, mild responders, and high responders. To figure out exactly why the drug only worked for certain subjects, the scientists prepared incredibly thin slices of the rodents’ brains and kept the tissue alive in an oxygenated fluid bath.

They focused specifically on the central amygdala, a dense cluster of neurons that acts as a major hub for processing fear, stress, and negative emotional states. They utilized microscopic glass electrodes to record the faint electrical currents flowing across the membranes of individual brain cells within this region.

This advanced technique allowed them to observe the real-time activity of gamma-aminobutyric acid, commonly known as GABA. This chemical acts as the primary inhibitory messenger in the mammalian nervous system, functioning like a biological brake pedal to slow down chaotic electrical firing. During the acute phase of alcohol withdrawal, this braking system heavily dysregulates.

In the high-responding animals, bathing the brain slices in ivermectin resulted in a sustained increase in the frequency of calming GABA signals. This suggests that the drug successfully engaged the target receptors and facilitated the release of inhibitory chemicals, which likely reduced the animals’ internal urge to drink.

The drug produced a very different outcome in the non-responding animals. While it slightly changed the exact timing of the electrical currents, it failed to elevate the overall frequency of the inhibitory signals. The researchers suspect that in these animals, the medication might have interacted with other incidental receptors on the cell surface rather than properly engaging the primary target mechanism.

Moving pharmaceuticals from rodent experiments to human clinics presents massive hurdles. Ivermectin often struggles to cross the blood-brain barrier, which acts as a protective cellular shield around the human central nervous system. Achieving the necessary drug concentrations in the human brain might be difficult with standard oral pill dosing alone.

Future research will address these chemical delivery issues. Scientists might explore combination therapies, pairing ivermectin with complementary chemical agents that temporarily bypass the brain’s defense pumps, allowing more of the drug to reach the central amygdala. Other studies will attempt to map exactly which types of brain cells express the highest numbers of these targeted receptors to narrow down the mechanical focus.

Ultimately, the study highlights the necessity of matching the right pharmacological treatment to the correct genetic profile. Future clinical trials evaluating this cellular pathway will likely need to pre-screen human participants for specific genetic markers. By identifying who is most biologically primed to respond, medical professionals could eventually deliver strictly tailored treatments for severe alcohol dependence.

The study, “Ivermectin Reduces Withdrawal-Induced Alcohol Intake in Rats: Association with CeA GABAergic Enhancement and P2rx4 Genetic Liability,” was authored by Paola Campo, Ran Qiao, Michelle R. Doyle, Daniel Munro, Benjamin J. Johnson, Abraham A. Palmer, Marsida Kallupi, and Giordano de Guglielmo.